ANIK
Anika Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$20.22
+1.20%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$20.08
From 52W high−8.22%
Volume66535.00
Market cap$270.60M
P/E (TTM)—
P/S (TTM)2.2x
Div yield—
Key dataOct 19, 2026
Open
$20.08
From 52W high
−8.22%
Volume
66535.00
Market cap
$270.60M
ValuationView details →
P/E (Fwd)
21.5x
EV/EBITDA
93.9x
P/E (TTM)
—
RSI (14)
51.1
MomentumView details →
1D Return
+1.20%
YTD Return
+110.82%
SummaryUpdated Jun 1, 2026
Anika Therapeutics, Inc. (NASDAQ:ANIK) is a joint preservation company founded in 1983 and headquartered in Bedford, Massachusetts. The company went public in 1993 and has established itself as a specialized medical device manufacturer focused on orthopedic care solutions. Anika develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology, serving both domestic and international markets. The company has undergone significant strategic restructuring in recent years, divesting non-core assets like Arthrosurface and Parcus Medical to focus exclusively on its proprietary hyaluronic acid-based product portfolio.
Similar companies
Latest newsMore news →
Anika Therapeutics reported its second-quarter financial results for 2026, showing higher revenue, expanded gross margin, and the strongest adjusted EBITDA since 2020.83d agoAnika Therapeutics, Inc. entered into a Fifth Amendment to its credit agreement, establishing a $50.0 million senior secured revolving line of credit with an option to increase to $100.0 million, maturing on July 10, 2031.98d ago